

1-29-00

A

WORKMAN NYDEGGER & SEELEY

ATTORNEYS AT LAW

A PROFESSIONAL CORPORATION

1000 EAGLE GATE TOWER

60 EAST SOUTH TEMPLE

SALT LAKE CITY, UTAH 84111

TELEPHONE (801) 533-9800

FACSIMILE (801) 328-1707

RICK D. NYDEGGER
DAVID O. SEELEY
BRENT P. LORIMER
THOMAS R. VUKSINICK
LARRY R. LAYCOCK
JONATHAN W. RICHARDS
DAVID R. WRIGHT
JOHN C. STRINGHAM
BRADLEY K. DESANDRO
JOHN M. GUINN
CHARLES L. ROBERTS
GREGORY M. TAYLOR
DANA L. TANGREN
KEVIN B. LAURENCE
ERIC L. MASCHOFF
CHARLES J. VEVERKA
ROBYN L. PHILLIPS
RICHARD C. GILMORE†
DAVID B. DELLENBACH
KEVIN K. JOHANSON
L. DAVID GRIFFIN

R. BURNS ISRAELEN
DAVID R. TODD
FRASER D. ROY
CARL T. REED
JESÚS JUANÓS I TIMONEDA, Ph.D.
R. PARRISH FREEMAN, Jr.
PETER F. MALEN, Jr.
ADRIAN J. LEE
DAVID B. TINGEY
L. REX SEARS, Ph.D.
ERIC M. KAMERATH
ROBERT E. AYCOCK
JENS C. JENKINS
KEVIN W. STINGER
WILLIAM J. ATHAY

ADMITTED ONLY IN CALIFORNIA

H ROSS WORKMAN
OF COUNSEL

PATENT
TRADEMARK
COPYRIGHT
TRADE SECRETS
UNFAIR COMPETITION
LICENSING
COMPLEX LITIGATION

MAILING ADDRESS:

P.O. BOX 45862

SALT LAKE CITY, UT 84145

INTERNET

HOME PAGE: <http://www.wnspat.com>

GENERAL E-MAIL: info@wnspat.com

Express Mail Label No.EL746190296US

PATENT APPLICATION

Docket No: 13352.6.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Prior Application:
Examiner: Arthur L. Corbin
Art Unit: 1761

Box PATENT APPLICATION
Commissioner for Patents
Washington, DC 20231

TRANSMITTAL FOR DIVISIONAL PATENT APPLICATION

Sir:

This is a request for filing a divisional application under 37 C.F.R. § 1.53(b), of pending prior application Serial No. 09/394,217, filed on September 13, 1999, of Narayan K. Athanikar and Scott A. Gubler for PROCESS FOR MANUFACTURING A PHARMACEUTICAL CHEWING GUM, (hereinafter "the Parent Application").

A. Enclosed Application Elements and Accompanying Parts

x A specification, claims, abstract, and cover page in total comprising eighteen (18) pages.

_____ sheets of drawings.

x A copy of the Declaration, Power of Attorney, and Petition as originally filed in the Parent Application and currently in effect.

x Entitlement to small entity status under 37 C.F.R. §§ 1.9 and 1.27.

JC912 U.S. PTO
09/724144
11/28/00

11/28/00

09724144-13352.6.1

☐ A Declaration Claiming Small Entity Status is enclosed.

☒ A Declaration Claiming Small Entity Status was filed in the Parent Application and such status is still proper and desired.

☒ A Certificate of Mailing by "Express Mail" certifying a filing date for the enclosed application by use of Express Mail Label No. EL746190296US.

☐ A Preliminary Amendment.

☐ An Associate Power of Attorney.

B. Instructions and Averments

☒ Priority to United States Patent Application Serial No. 09/394,217 filed on September 13, 1999 is claimed under 35 U.S.C. § 120.

☒ The Parent Application is assigned of record to Deseret Laboratories, Inc. and Josman Laboratories, Inc., as recorded at reel 010583, frames 0207.

C. Payments

The filing fee has been calculated as shown below.

			Small Entity			Other Than a Small Entity	
For	No. Filed	No. Extra	Rate	Fee	or	Rate	Fee
Basic Fee				\$355			\$710
Total Claims	7 - 20 =	0	x 9 =	\$ 0		x 18 =	\$
Ind. Claims	1 - 3 =	0	x 40 =	\$ 0		x 80 =	\$
Multiple Presented	Dependent	Claims	+135 =	\$		+ 270 =	\$
			Total	\$355		Total	\$

☒ Credit Card Payment Form PTO-2038 authorizing payment of \$355.00 is enclosed.

☐ Please debit Deposit Account No. 23-3178 in the amount of \$_____ for the government filing fee.

☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 23-3178. A duplicate copy of this letter is enclosed.


☒ Any additional filing fees required under 37 C.F.R. § 1.16.

☒ Any patent application processing fees under 37 C.F.R. § 1.17.

Please address all future correspondence in connection with the above-identified patent application to the attention of the undersigned.

Dated this 28th day of November 2000.

Respectfully submitted,


Gregory M. Taylor
Attorney for Applicant
Registration No. 34,263



022913

PATENT TRADEMARK OFFICE

PATENT APPLICATION
Docket No. 13352.6.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

"Express Mail" Mailing Label No.: EL746190296US

Date of Deposit: November 28, 2000


CERTIFICATE OF MAILING BY "EXPRESS MAIL"

I hereby certify that the following documents are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated below in an envelope addressed to Box PATENT APPLICATION, Commissioner for Patents, Washington, DC 20231:

- Divisional Patent Application in the names of Narayan K. Athanikar and Scott A. Gubler for PROCESS FOR MANUFACTURING A PHARMACEUTICAL CHEWING GUM (18) pages
- Copy of Declaration, Power of Attorney and Petition (3 pgs.)
- Transmittal Letter (3 pgs.)
- Credit Card Payment Form PTO-2038 for \$355.00
- Postcard

Dated this 28th day of November 2000.

Respectfully submitted,



Gregory M. Taylor
Attorney for Applicant
Registration No. 34,263



022913

PATENT TRADEMARK OFFICE



00366 11/28/00

Express Mailing Label No. EL 746190296US

PATENT APPLICATION
Docket No. 13352.6.1

UNITED STATES PATENT APPLICATION

of

NARAYAN K. ATHANIKAR


and

SCOTT A. GUBLER

for

**PROCESS FOR MANUFACTURING
A PHARMACEUTICAL CHEWING GUM**

WORKMAN, NYDEGGER & SEELEY
A PROFESSIONAL CORPORATION
ATTORNEYS AT LAW
1000 EAGLE GATE TOWER
60 EAST SOUTH TEMPLE
SALT LAKE CITY, UTAH 84111



FIELD OF THE INVENTION

The present invention relates to processes for producing chewing gum tablets as dosage forms for pharmaceutical therapeutic agents, and in particular to a process for making a pharmaceutical chewing gum dosage form having a more accurate and uniform dose of the pharmaceutical active ingredient.

BACKGROUND

Pharmaceutical therapeutic agents, such as drugs, are formulated in a variety of dosage forms, depending upon the target absorption site of the drug, the intended time profile for absorption, the solubility characteristics of the drug, the susceptibility of the drug to various forms of attack in vivo, such as enzymatic degradation and organ uptake, and other considerations well-known to those skilled in the art. A large number of drugs are formulated in orally ingestible dosage forms for delivery into the gastrointestinal tract, where they are absorbed into the blood stream and carried to various organs or tissues where the pharmacological action is exerted. Typically, such dosage forms are capsules or tablets, which may further be provided with various coatings, to assist in passage through the gastrointestinal tract, or to provide a delayed or extended release profile. When more rapid therapeutic action is desired, or when the therapeutic agent is particularly susceptible to chemical or enzymatic attack in the gastrointestinal tract, a preferred route of delivery is injection into the blood stream, and the corresponding dosage form is an injectable liquid or solution. Still other drugs are delivered topically to the skin, eyes, and various mucosal tissues, in dosage forms such as ointments, creams, gels and lotions.

1 A number of therapeutically useful drugs are capable of buccal absorption; *i.e.*,
2 absorption in the oral cavity, either sublingually or throughout the oral mucosal wall, or
3 by dissolution in the saliva and absorption in the throat, esophagus, or upper
4 gastrointestinal tract. For drugs having significant buccal and/or upper and lower
5 gastrointestinal tract absorption, oral dosage forms taking advantage of the absorption,
6 such as lozenges, chewable tablets, and chewing gum, are particularly advantageous.
7 Such dosage forms permit more rapid therapeutic action compared to per-oral
8 (swallowed) dosage forms, and the topically absorbed therapeutic agent also partially
9 escapes liver metabolism.

10 The chewing gum dosage form is particularly attractive due to its ease of
11 administration and the generally acceptable or even pleasant qualities of chewing gum.
12 These attractive properties can significantly improve patient compliance with the dosage
13 regimen. Thus, for example, U.S. Patent No. 4,971,079 is directed to chewing gum
14 compositions having an anti-nicotine therapeutic effect, for use in facilitating cessation of
15 smoking. Likewise, U.S. Patent No. 5,922,347 is directed to chewing gum compositions
16 containing acetylsalicylic acid, a well-known anti-inflammatory and analgesic compound.

17 The conventional chewing gum processing technology involves melting a gum
18 base in, for example, a sigma blender, and adding components such as sweeteners and
19 flavorants to the melt. The melted mass is then extruded, rolled into sheets, and cut to the
20 desired shape on the rollers. This conventional technology, however, suffers from
21 several disadvantages, when applied to the preparation of pharmaceutical chewing gum
22 dosage forms. For example, the elevated temperatures used in the melt can adversely
23 affect the chemical stability of the therapeutic agent contained therein. In addition, the
24 melting and mixing process of the highly viscous gum mass makes controlling the

1 accuracy and uniformity of the drug dose difficult, and this difficulty is further
2 exacerbated by the lack of a precise form, shape or weight of the dosage form. Further,
3 the gum processing technology is not easily adapted to incorporate the stringent sanitary
4 manufacturing conditions required for production of pharmaceutical products, and the
5 concomitant process validation and control measures. In addition, conventional gum
6 processing technology is generally poorly suited for high-speed, more economical,
7 production.

8 Several patents are directed to improved methods of processing chewing gums, in
9 order to overcome some of the disadvantages described above. U.S. Patent No.
10 4,000,321, for example, is directed to a process for preparing chewing gum, in which a
11 chewing gum composition is cooled to -15 °C to facilitate fragmentation, and the cooled
12 composition is pulverized with a crusher, hammer mill, pelletizer or turbomill. The
13 pulverized product is then melted to cause the pulverized pieces to co-adhere, forming a
14 chewing gum reportedly having low specific gravity and a soft chewing texture. The
15 process, however, suffers from all of the disadvantages associated with heating, process
16 speed, poorly defined dosage forms and weights described above, and is not well-suited
17 for making a pharmaceutical chewing gum dosage form.

18 U.S. Patent No. 4,753,805 is directed to a chewing gum composition in the form
19 of a tablet having a low moisture content. The tablet is produced by grinding a chewing
20 gum composition, blending the ground composition with a compression aid, and
21 compressing the granulated product to form a tablet. Grinding of the chewing gum
22 composition, typically a difficult process because of the tendency for the gum to stick to
23 the grinding apparatus, is accomplished by the use of 2-8% by weight of a grinding aid
24 such as an alkaline metal phosphate, an alkaline earth metal phosphate, or a maltodextrin.

1 The use of such grinding aids, however, is disadvantageous. The metal phosphate salts
2 are highly alkaline, and such alkalinity may be incompatible with acidic ionizable
3 therapeutic agents, for example. In addition, the grinding aid remains in the composition
4 and ultimately in the chewing gum tablet, and the presence of a large amount of metal
5 phosphate in the dosage form is potentially problematic from therapeutic and safety
6 perspectives.

7 Thus, there is a need for processes to produce dosage forms of buccally
8 absorbable therapeutic agents which do not suffer from the disadvantages of conventional
9 pharmaceutical chewing gum formulations.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a process for preparing chewing gum dosage forms of therapeutic agents topically effective toward the gastrointestinal tract having improved dose accuracy and uniformity.

It is also an object of the present invention to provide a process for preparing chewing gum dosage forms of therapeutic agents topically effective toward the gastrointestinal tract having a precise and well-defined form, shape and weight.

It is also an object of the present invention to provide a process for preparing chewing gum dosage forms of therapeutic agents topically effective toward the gastrointestinal tract, wherein the therapeutic agent is not subjected to elevated temperatures.

It is further an object of the present invention to provide processes for preparing chewing gum dosage forms of therapeutic agents topically effective toward the gastrointestinal tract capable of being carried out in high-speed, efficient manufacturing processes.

It is still a further object of the present invention to provide chewing gum dosage forms of therapeutic agents topically effective toward the gastrointestinal tract.

The foregoing objects and other advantages are achieved by the process of the present invention, in which a chewing gum composition is cooled to a temperature at which the composition is brittle, and the composition is ground while brittle to form a fine powder. In a preferred process, the composition is cooled by mixing with a coolant, such as solid carbon dioxide, and the mixture is ground to a powder. The powder can be mixed with a pharmaceutical active ingredient capable of buccal and/or upper or lower gastrointestinal tract topical absorption (*i.e.*, topically effective toward the gastrointestinal

tract), and formed into a tablet. Preferably, the mixture of the powder, pharmaceutical active ingredient, and other additives such as coating agents, binders, additional active ingredients, and sweeteners, are granulated in a fluidized bed granulator prior to forming the mixture into a tablet. The resulting tablet provides an improved dosage form of the pharmaceutical active ingredient.

Thus, in one aspect, the present invention provides a process for preparing a chewing gum tablet, the process including the steps of cooling a chewing gum composition to a temperature at which the composition is brittle, grinding the cooled chewing gum composition, and forming the ground chewing gum composition into a tablet.

In another aspect, the present invention provides a process for preparing a chewing gum tablet, the process including the steps of providing a mixture including a chewing gum composition and solid carbon dioxide, grinding the mixture to form a powder, removing the solid carbon dioxide from the powder, and forming the powder into a tablet.

In another aspect, the present invention provides a process for preparing a dosage form of an active ingredient topically effective toward the gastrointestinal tract, the process including the steps of providing a mixture including a chewing gum composition and solid carbon dioxide, grinding the mixture to form a powder, removing the solid carbon dioxide from the powder, mixing the powder with a composition including the active ingredient to form an active ingredient-containing powder, granulating the active ingredient-containing powder in a fluidized bed granulator, and compressing the granules into a tablet to form a dosage form containing the active ingredient.

1 In another aspect, the present invention provides a chewing gum dosage form of
2 an active ingredient topically effective toward the gastrointestinal tract, the dosage form
3 including a gum base and an active ingredient and being formed of a plurality of
4 compressed granules containing the gum base and active ingredient.

5 These and other objects and features of the present invention will become more
6 fully apparent from the following description and appended claims, or may be learned by
7 the practice of the invention as set forth hereinafter.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is directed to processes for improved production of pharmaceutical chewing gum dosage forms. The processes of the present invention enable production of chewing gum tablets without the disadvantages of heating the therapeutic agent, and without problems associated with inaccuracy and non-uniformity of therapeutic agent doses characteristic of conventional chewing gum processes. The present invention achieves these and other significant advantages by a process in which a chewing gum composition is cooled to a brittle temperature, ground while at a brittle temperature to form a powder, and formed into a tablet. The pharmaceutical therapeutic agent, or active ingredient, is readily mixed with the powdered gum composition prior to tablet formation, to produce a uniform and accurate mixture, from which a well-defined and precise tablet dosage form can be prepared by tabletization.

In one step of the process of the present invention, a chewing gum composition is cooled to a temperature at which the composition is brittle. The chewing gum composition can be any chewing gum composition, such as conventional compositions known in the art. In general, such compositions include a chewing gum base, to which may be added flavorants, sweeteners, colorants, and other ingredients known in the art. The chewing gum base is typically a natural or synthetic elastomer, such as rubber, chicle, lechi caspi, jelutong, polyisobutylene, an isobutylene-isoprene copolymer, a styrene-butadiene copolymer, or other suitable gum base known in the art. In order to facilitate the subsequent grinding step, the chewing gum composition is preferably in the form of chips, pellets, or other relatively small particles.

The chewing gum composition is cooled to a temperature at which the composition is brittle. It should be appreciated that even a mildly cooled chewing gum

1 composition will possess some degree of brittleness; however, to be suitable for the
2 process of the present invention, the composition is cooled to a temperature at which the
3 composition is sufficiently brittle such that the brittleness is maintained during the
4 subsequent grinding step without adhesion to the grinding apparatus. The appropriate
5 temperature is determined in part by the specific composition of the chewing gum, and is
6 easily determined empirically by observing the properties of the cooled chewing gum
7 composition. Thus, for example, a chewing gum composition cooled to a temperature
8 sufficiently low can be ground in, for example, a mill grinder, without the composition
9 sticking to the grinder parts. Preferably, the temperature will be less than -15 °C, more
10 preferably less than -30 °C, and still more preferably less than about -40°C.

11 The cooling can be carried out by any of a variety of cooling processes. The
12 chewing gum composition can be frozen in a conventional freezer apparatus capable of
13 reaching the very low temperatures needed to achieve the requisite brittleness.
14 Preferably, however, the chewing gum composition is cooled by contacting with a
15 coolant. The coolant can be any substance capable of cooling the chewing gum
16 composition to the desired temperature and can be, for example, a cryogenic liquid such
17 as liquid nitrogen, a cold solid such as solid carbon dioxide, or a cold gas such as the
18 gaseous boil-off from a cryogenic liquid. The coolant should be chosen so that the
19 coolant does not interact adversely with the chewing gum composition or with the mixing
20 or grinding apparatuses used in the present process. In addition, the coolant should not
21 produce a substance upon warming that suffers from such adverse interactions, or that
22 leaves a residue that adversely affects subsequent processing or presents potential safety
23 hazards when the chewing gum tablet is chewed. For example, a coolant such as water
24 ice, even if cooled to a sufficiently low temperature, would not be preferred, as any water

1 ice that melts will form liquid water, which is absorbed by the chewing gum composition.
2 Likewise, a coolant such as a hydrocarbon slush would not be preferred, since any
3 hydrocarbon residue remaining in the chewing gum composition would present potential
4 safety hazards when the chewing gum tablet is consumed.

5 In accordance with the present invention, and in a particularly preferred aspect, it
6 has been surprisingly found that by mixing a chewing gum composition with solid carbon
7 dioxide (dry ice), the chewing gum composition can be cooled to a brittle temperature
8 without the undesirable effects discussed above. At the sublimation temperature, -78.5
9 °C, solid carbon dioxide is sufficiently cold to ensure that the chewing gum composition
10 is suitably brittle. Of course, the solid carbon dioxide can be cooled to an even lower
11 temperature, if desired. Upon warming, the solid carbon dioxide sublimates to form carbon
12 dioxide gas, which does not react with the chewing gum composition, is not absorbed by
13 the composition, and does not interact adversely with processing apparatuses. Further,
14 the gaseous, non-reactive nature of the sublimation product ensures that no undesirable
15 and potentially hazardous residue of the coolant remains in the chewing gum tablet
16 product. Preferably, the solid carbon dioxide coolant is provided in pelletized form to
17 facilitate further processing steps.

18 Alternatively, the steps of cooling the chewing gum composition and grinding the
19 composition can be combined into a single step by, for example, cooling the grinding
20 apparatus itself, such as by contacting the grinding apparatus with a coolant. For
21 example, in this alternative aspect, the grinding apparatus can be placed in a cooling
22 jacket of liquid nitrogen or other cold liquid. For more efficient cooling, in this
23 embodiment, the chewing gum composition is preferably pre-cooled, although the pre-
24 cooling need not be to a temperature as low as the brittle temperature. It should be

1 appreciated that even in the preferred embodiment, wherein the chewing gum
2 composition is cooled by mixing with a coolant, it may also be advantageous to cool the
3 grinding apparatus as well.

4 If desired, the chewing gum composition can be mixed with an anti-caking agent
5 prior to the grinding step, and the use of an anti-caking agent is preferred. Such anti-
6 caking agents are known in the art. A preferred anti-caking agent is precipitated silicon
7 dioxide. In a preferred embodiment in which the chewing gum composition is mixed
8 with solid carbon dioxide and an anti-caking agent prior to grinding, the anti-caking agent
9 helps to prevent agglomeration of the subsequently ground chewing gum particles, upon
10 sublimation of the solid carbon dioxide.

11 If a coolant, such as solid carbon dioxide, and other components, such as an anti-
12 caking agent are used, the chewing gum composition and other substances can be
13 combined using a conventional mixing apparatus, such as a vented V-blender.

14 The chewing gum composition, and other components such as coolant and anti-
15 caking agent, are ground to form a fine powder. The grinding can be carried out using
16 any conventional grinding apparatus, such as a mill grinder. In a preferred embodiment,
17 a mixture of a chewing gum composition, solid carbon dioxide, and precipitated silica is
18 provided, and the mixture is introduced into a mill grinder. In this embodiment, the
19 mixture is ground to a fine powder, and the solid carbon dioxide remains present during
20 the grinding process. It has been surprisingly found that by co-grinding the chewing gum
21 composition and solid carbon dioxide, the chewing gum composition can be ground into
22 a fine powder, without any adverse adhesion to the grinding apparatus.

23 The desired properties of the ground chewing gum composition are better
24 achieved when the composition is kept at a very low temperature throughout the grinding

1 process. Thus, in a particularly preferred process, a mixture of chewing gum
2 composition, solid carbon dioxide and precipitated silica is ground in a mill grinder in a
3 first grinding step, additional solid carbon dioxide and precipitated silica are added to the
4 ground composition, and the composition is further ground in a second grinding step.
5 This two-step grinding process advantageously keeps the chewing gum composition at a
6 very low temperature. Although not wishing to be bound by theory, it is further believed
7 that the presence of the solid carbon dioxide particles, in addition to providing the
8 necessary cooling, also serves to enhance the efficiency of the grinding process. It should
9 be appreciated that although a two-step grinding process is described herein, the number
10 of steps is not particularly limited. Thus, a process in which additional solid carbon
11 dioxide and/or precipitated silica are added in multiple steps, or even in a slow,
12 continuous stream, may also be used if desired.

13 After the composition is ground to a powder, the coolant can be removed by, for
14 example, allowing the coolant to evaporate. Using the preferred coolant of solid carbon
15 dioxide, the coolant is removed simply by allowing the solid carbon dioxide to sublime,
16 releasing harmless carbon dioxide gas and leaving no undesirable contaminants. The
17 ground composition can be stored such that the carbon dioxide gas can escape, as for
18 example in loosely closed plastic bags. Alternatively, the carbon dioxide can be removed
19 more rapidly by processing the ground composition in a fluidized bed reactor.

20 Once the coolant has been removed from the powder, the powder can be mixed
21 with other ingredients as desired, before forming the powder into a tablet. Such
22 ingredients can be any ingredient known to be incorporated into chewing gum and not
23 incompatible with tablet formation, such as coating agents, binders, lubricants,
24 sweeteners and the like. Preferably, a pharmaceutical active ingredient topically effective

1 toward the gastrointestinal tract is added in an amount such that the tablet ultimately
2 formed includes a therapeutically effective dose of the active ingredient. As used herein,
3 the term "topically effective toward the gastrointestinal tract" means having significant
4 absorption in the buccal cavity and/or the mucous layer of the upper and/or lower
5 gastrointestinal tract. The active ingredient can be any active ingredient having such
6 topical absorption, such as, for example, gastrointestinal anti-infective drugs, anti-
7 diarrheal drugs, anti-cholic drugs, cardiovascular drugs such as nitroglycerin, and
8 calcium channel blocking agents such as nifedipine.

9 Such ingredients can be combined with the powder by blending, in for example, a
10 sigma mill, or a high shear mixer. If a conventional blending apparatus is used, the
11 powder mixture should include sufficient amounts of binder to enable effective
12 processing of the mixture. Such binders, well-known in the art, are typically aqueous,
13 and the large amounts of aqueous binder necessary to enable tabletization from a blended
14 mixture are not preferred, as the mixture tends to swell and to develop a disadvantageous
15 stickiness that makes tabletization less efficient. However, although not preferred, such
16 blending processes can still be used in the process of the present invention.

17 In a preferred process, it has been surprisingly found that the powdered chewing
18 gum composition produced by the process described above can be combined with other
19 ingredients, such as coating agents, binders, sweeteners and active ingredients, in a
20 fluidized bed reactor. The use of a fluidized bed reactor is particularly advantageous, as
21 the process partially rebuilds the powder into granules, as well as coats the powder
22 particles and/or granules with a coating agent, thereby minimizing undesired particle
23 agglomeration. In this embodiment, the temperature of the process should be controlled.
24 If the temperature is too low, the mixture (the "blend") will stick because of a low

1 evaporation rate as the binding solution is sprayed on the blend. The granules that
2 develop are then too large for subsequent tabletization. If the temperature is too high, the
3 blend can soften, with the same disadvantageous results. With these considerations in
4 mind, one skilled in the art can readily determine the appropriate process temperature by
5 observing and optimizing the properties of the granules produced. To reduce the
6 processing time, the fluid bed granulator can be pre-heated to the chosen processing
7 temperature prior to adding the powder mixture. After granulation, the granulate can be
8 discharged onto screens, and any granules that are too large can be removed.

9 In a preferred process, the powder mixture, containing the powdered chewing
10 gum composition, active ingredient, and other additives, is weighed into individual
11 "charges" for the fluid bed granulator. After processing as described above, and
12 screening, the individual charges are then preferably recombined and mixed in a V-
13 blender, and the resultant "cross-blend" is then discharged across a screen to again
14 remove any granules that are too large. It is particularly advantageous to sample the
15 cross-blend discharge by taking multiple samples from the discharge stream, for analysis
16 of the active ingredient. Thus, the discharge mixture can be stored while the multiple
17 samples are analyzed, to insure that the desired level and uniformity of level of active
18 ingredient are present. If necessary, additional active ingredient can then be added.

19 The discharge mixture is again placed in a V-blender, and any additional active
20 ingredient added. In addition, an anti-adherent is preferably added at this time, along
21 with any other desired excipients or inactive ingredients. A preferred anti-adherent is
22 talc. The mixture can then be discharged, again screened, and staged for compression.

23 Compression to form tablets can be carried out by any conventional process, such
24 as a punching process. Of course, the punching process should be monitored for signs of

1 sticking to the punches, and the apparatus cleaned, and/or coated with additional anti-
2 adherent as needed.

3 In another aspect, the present invention is directed to chewing gum dosage forms
4 of a pharmaceutical active ingredient topically effective toward the gastrointestinal tract,
5 the dosage form being a tablet formed of compressed granules of a gum base and the
6 active ingredient. The granules forming the tablet can be of a size convenient for
7 tabletization, typically from about 15 to about 30 mesh size, and preferably about 20 to
8 about 25 mesh size. The tablets can be produced by any of the methods described above.
9 Advantageously, the tablet does not contain any residue of a grinding aid, such as an
10 alkaline phosphate.

11 The present invention may be embodied in other specific forms without departing
12 from its spirit or essential characteristics. The described embodiments are to be
13 considered in all respects only as illustrative and not restrictive. The scope of the
14 invention is, therefore, indicated by the appended claims rather than by the foregoing
15 description. All changes which come within the meaning and range of equivalency of the
16 claims are to be embraced within their scope.

17 What is claimed and desired to be secured by United States Letters Patent is:
18
19
20
21
22
23
24

1 1. A dosage form of a pharmaceutical chewing gum comprising a plurality of
2 particles compressed to form a tablet, the particles comprising a chewing gum
3 composition and a pharmaceutically active ingredient topically effective toward the
4 gastrointestinal tract.

6 2. The dosage form of claim 1, wherein the particles have an average size of
7 about 15 mesh to about 30 mesh.

9 3. The dosage form of claim 1, wherein the tablet is substantially free of a
10 grinding aid or a grinding aid residue.

12 4. The dosage form of claim 1, wherein the particles further comprise an
13 anti-caking agent.

15 5. The dosage form of claim 4, wherein the anti-caking agent is precipitated
16 silicon dioxide.

18 6. The dosage form of claim 1, wherein the particles are coated with a
19 coating agent.

21 7. The dosage form of claim 1, wherein the particles further comprise at least
22 one additive selected from the group consisting of binders, coating agents, sweeteners,
23 and additional active ingredients.

24

ABSTRACT

The present invention provides a process for preparing a chewing gum tablet, in which a chewing gum composition is cooled to a temperature at which the composition is brittle, and the composition is ground while brittle to form a fine powder. In a preferred process, the composition is cooled by mixing with a coolant, such as solid carbon dioxide, and the mixture is ground to a powder. The powder can be mixed with a pharmaceutical active ingredient capable of topical absorption in the buccal cavity or in the mucous layer of the upper or lower intestinal tract, and formed into a tablet. Preferably, the mixture of the powder, pharmaceutical active ingredient, and other additives such as coating agents, binders, additional active ingredients, and sweeteners, are granulated in a fluidized bed granulator prior to forming the mixture into a tablet. The resulting tablet provides a dosage form of the pharmaceutical active ingredient having a more accurate and uniform dose of the active ingredient.

G:\DATA\PAT\133526 1.pat.DOC

DECLARATION, POWER OF ATTORNEY, AND PETITION

We,

- (1) Name: Narayan K. Athanikar
Address: 31 Carson
Irvine, California 92620-3312
Citizenship: India
- (2) Name: Scott A. Gubler
Address: 1414 East 3850 South
St. George, Utah 84790
Citizenship: United States

we declare: that our citizenship, residence address, and post office address are as set forth above; that we verily believe we are the original, first, and joint inventors of the subject matter of the invention or discovery entitled PROCESS FOR MANUFACTURING A PHARMACEUTICAL CHEWING GUM for which a patent is sought and which is described and claimed in the specification which was filed in the United States Patent and Trademark Office as Serial No. 09/394,217 on September 13, 1999; that we have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to herein; and that we acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Section 1.56(a) of Title 37 of the Code of Federal Regulations.

We declare further that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States


Code, and that such willful, false statements may jeopardize the validity of the application or any patent issuing thereon.

We hereby appoint as our attorneys and/or patent agents: RICK D. NYDEGGER, Registration No. 28,651; DAVID O. SEELEY, Registration No. 30,148; JONATHAN W. RICHARDS, Registration No. 29,843; JOHN C. STRINGHAM, Registration No. 40,831; BRADLEY K. DeSANDRO, Registration No. 34,521; JOHN M. GUYNN, Registration No. 36,153; CHARLES L. ROBERTS, Registration No. 32,434; GREGORY M. TAYLOR, Registration No. 34,263; DANA L. TANGREN, Registration No. 37,246; KEVIN B. LAURENCE, Registration No. 38,219; ERIC L. MASCHOFF, Registration No. 36,596; C. J. VEVERKA, Registration No. 40,858; ROBYN L. PHILLIPS, Registration No. 39,330; RICHARD C. GILMORE, Registration No. 37,335; DAVID B. DELLENBACH, Registration No. 39,166; KEVIN K. JOHANSON, Registration No. 38,506; DAVID L. GRIFFIN, Registration No. 44,136; R. BURNS ISRAELSEN, Registration No. 42,685; DAVID R. TODD, Registration No. 41,348; JESÚS JUANÓS i TIMONEDA, Registration No. 43,332; STEPHEN D. PRODNUK, Registration No. 43,020; R. PARRISH FREEMAN, JR., Registration No. 42,556; ADRIAN J. LEE, Registration No. 42,785; and KYLE H. FLINDT, Registration No. 42,539, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith. All correspondence and telephonic communications should be directed to:

DAVID O. SEELEY
WORKMAN, NYDEGGER & SEELEY
1000 Eagle Gate Tower
60 East South Temple
Salt Lake City, Utah 84111
Telephone: (801) 533-9800
Facsimile: (801) 328-1707


Wherefore, we pray that Letters Patent be granted to us for the invention or discovery described and claimed in the foregoing specification and claims, declaration, power of attorney, and this petition.

Dated this 23 day of February 2000.

Inventor: 

Narayan K. Athanikar
31 Carson
Irvine, California 92620-3312

Dated this 23 day of February 2000.

Inventor: 

Scott A. Gubler
1414 East 3850 South
St. George, Utah 84790

G:\DATA\WPDOCS3\SDP\13352.6\declaration.doc